Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Novabac is a topical antibacterial skin wash containing 5% tea tree oil (TTO), derived from the plant *Melaleuca alternifolia*, as its active ingredient. Developed by researchers at the Belfast Health & Social Care Trust, it is designed for the prevention of methicillin-resistant *Staphylococcus aureus* (MRSA) colonization in critically ill adults within intensive care units (ICUs). The mechanism of action involves the disruption of the bacterial cell membrane and the inhibition of microbial respiration, providing a natural alternative to standard antiseptic washes. Clinical evaluation includes a randomized controlled trial (ISRCTN65190967) comparing its efficacy against standard care for reducing MRSA acquisition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Novabac.